Hottest Stocks: First Financial Bancorp., World Acceptance Corp. (NASDAQ:WRLD), Cellular Biomedicine Group (NASDAQ:CBMG), Baidu Inc (NASDAQ:BIDU)

Shaw Communications, Inc. (NYSE:SJR) shares moved up 0.64% in last trading session and ended the day at $20.48. SJR Gross Margin is 43.10% and its has a return on assets of 5.40%. Shaw Communications, Inc. (NYSE:SJR) quarterly performance is -2.63%.

Shaw Communications, Inc. (NYSE:SJR) will be releasing its consolidated results for the Fourth Quarter (ending August 31, 2015) the morning of Thursday, October 22, 2015. A conference call with Shaw Senior Management and the financial community is scheduled as follows. Press/Media and the public will be able to participate in listen-only mode.

First Financial Bancorp. (NASDAQ:FFBC) ended the last trading day at $18.55. Company weekly volatility is calculated as 2.30% and price to cash ratio as 5.43. First Financial Bancorp. (NASDAQ:FFBC) showed a weekly performance of -3.13%.

First Bancorp (NASDAQ:FBNC) declared a quarterly dividend. Shareholders of record on Wednesday, September 30th will be given a dividend of 0.08 per share by the financial services provider on Friday, October 23rd. This represents a $0.32 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Monday, September 28th.

On 14 October, World Acceptance Corp. (NASDAQ:WRLD) shares moved up 1.82% and was closed at $29.10. WRLD EPS growth in last 5 year was 21.70%. World Acceptance Corp. (NASDAQ:WRLD) year to date (YTD) performance is -63.37%.

Zacks cut shares of World Acceptance Corp. (NASDAQ:WRLD) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) shares remains unchanged in last trading session and ended the day at $18.02. CBMG Gross Margin is 37.50% and its has a return on assets of -33.50%. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) quarterly performance is -39.20%.

On Sept. 28, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) announced results from an expanded Phase I/II clinical trial evaluating the safety, feasibility and anti-tumor activity of its Chimeric Antigen Receptor-Modified T-Cells (CAR-T) immunotherapy (CBM-EGFR.1) targeting wild type EGFR (Epidermal Growth Factor Receptor) for the treatment of patients with EGFR expressing advanced relapsed/refractory solid tumors. Based on the results from 24 patients treated with CBM-EGFR.1 (17 patients with non-small cell lung cancer (NSCLC), 5 patients with cholangiocarcinoma, 1 patient with pancreatic cancer and 1 patient with renal cell carcinoma (RCC)), the early results showed that CBM-EGFR.1 immunotherapy was safe, well tolerated, and had positive signal of clinical activity in several indications.

Baidu Inc (ADR) (NASDAQ:BIDU) ended the last trading day at $145.02. Company weekly volatility is calculated as 2.75% and price to cash ratio as 4.32. Baidu Inc (ADR) (NASDAQ:BIDU) showed a weekly performance of 0.17%.

Baidu Inc (ADR) (NYSE:BIDU) news of a merger between two of its rivals, Meituan and Dianping, created doubt about the firms’ future. The new firm creates an online-to-offline competitor to Baidu, and Summit Reasearch’s Henry Guo reckons it’s “incrementally negative” for the Chinese firm going forward.